Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with type 2 diabetes and treated with oral anti-diabetic drugs (OADs) for at least 3 months~* HbA1c: 7.0-11.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy~* Body Mass Index (BMI) less than or equal 40 kg/m2~Exclusion Criteria:~* Subjects treated with insulin within the last three months~* Subjects with any serious medical condition~* Females of child bearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods~* Subjects using any drug (except for OADs), which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lira 0.6 + Met (Type: EXPERIMENTAL): Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Lira 1.2 + Met (Type: EXPERIMENTAL): Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Lira 1.8 + Met (Type: EXPERIMENTAL): Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Met Mono (Type: ACTIVE_COMPARATOR): Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
- Met + Glim (Type: ACTIVE_COMPARATOR): Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).